Ivana Mitrevska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ivana Mitrevska has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Olivera Paneva
Quality Assurance, ALKALOID AD Skopje, Skopje, Republic of North Macedonia
3 shared publicationsElizabeta Karadzinska
Quality Assurance, ALKALOID AD Skopje, Skopje, Republic of North Macedonia
2 shared publications- Gjorgji Petrushevski
Quality Control Pharmaceuticals ALKALOID AD Skopje , Skopje Republic of North Macedonia
2 shared publications Sonja Burcevska
Quality Assurance, ALKALOID AD Skopje, Skopje, Republic of North Macedonia
2 shared publications- Ana Mihailovska
Faculty of Natural and Technical Sciences Goce Delcev University , Stip , Republic of North Macedonia
1 shared publication - Dejan Mirakovski
Faculty of Natural and Technical Sciences Goce Delcev University , Stip , Republic of North Macedonia
1 shared publication
Latest Publications
- Open Access
- 29 August 2026
- Published by Springer Nature in Discover Sustainability
Sustainable pharmaceutical packaging under the European Union regulatory framework
- 29 August 2026
- Published by Springer Nature in Discover Sustainability
Open AccessSustainable pharmaceutical packaging under the European Union regulatory framework
- Open Access
- 22 August 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1)
Integrating Business Impact Analysis, Scenario-Based FMEA, and Business Continuity Planning in Pharmaceutical Manufacturing: A Product-Level Case Study
- 22 August 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1)
Open AccessIntegrating Business Impact Analysis, Scenario-Based FMEA, and Business Continuity Planning in Pharmaceutical Manufacturing: A Product-Level Case Study
- Open Access
- 1 June 2026
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 76 (2) , 1-11
SEM/EDS analysis as a complementary tool for continuous improvement of cefixime granules for oral suspension
The aim of this study was to evaluate scanning electron microscopy (SEM) combined with energy-dispersive X-ray spectroscopy (EDS) as complementary analytical tools for supporting continuous improvement in pharmaceutical granule manufacturing. Pilot-scale cefixime granules for oral suspension were prepared as defined process scenarios, including placebo, reference, intermediate, stress-exposed, and optimised batches. SEM was used to compare granule morphology, surface integrity, and agglomeration behaviour, whereas EDS provided qualitative and semi-quantitative information on localised elemental composition, with emphasis on sulfur as an API-related marker and oxygen-to--sulfur trends as surface-sensitive indicators of process- or stress-related variability. Intermediate and stress-exposed batches showed increased surface roughness, microstructural deterioration, and higher oxygen-to-sulfur ratios, whereas reference and optimised batches showed more uniform morphology and comparable elemental profiles. The findings indicate that SEM/EDS can provide useful material-level insight into process-related variability and may support root--cause investigation and process refinement. Overall, SEM/EDS is proposed as a complementary, localised, and semi-quantitative approach for supporting continuous improvement in pharmaceutical granule manufacturing.
- 1 June 2026
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 76 (2) , 1-11
Open AccessSEM/EDS analysis as a complementary tool for continuous improvement of cefixime granules for oral suspension
The aim of this study was to evaluate scanning electron microscopy (SEM) combined with energy-dispersive X-ray spectroscopy (EDS) as complementary analytical tools for supporting continuous improvement in pharmaceutical granule manufacturing. Pilot-scale cefixime granules for oral suspension were prepared as defined process scenarios, including placebo, reference, intermediate, stress-exposed, and optimised batches. SEM was used to compare granule morphology, surface integrity, and agglomeration behaviour, whereas EDS provided qualitative and semi-quantitative information on localised elemental composition, with emphasis on sulfur as an API-related marker and oxygen-to--sulfur trends as surface-sensitive indicators of process- or stress-related variability. Intermediate and stress-exposed batches showed increased surface roughness, microstructural deterioration, and higher oxygen-to-sulfur ratios, whereas reference and optimised batches showed more uniform morphology and comparable elemental profiles. The findings indicate that SEM/EDS can provide useful material-level insight into process-related variability and may support root--cause investigation and process refinement. Overall, SEM/EDS is proposed as a complementary, localised, and semi-quantitative approach for supporting continuous improvement in pharmaceutical granule manufacturing.
- Open Access
- 15 May 2026
- Published by MDPI AG in Preprints.org
Evaluation of a Post-Marketing Safety Signal Associated with a Novel Innovative Medicinal Product and Coordination with Regulatory Authorities
Background/Objectives: Following the market authorization of innovative medicinal products, continuous monitoring of safety signals is essential to ensure a favorable benefit–risk balance. This is particularly relevant for biological therapies used in oncology, where complex mechanisms of action and patient-related risk factors may contribute to rare but serious adverse events. The objective of this paper is to describe and critically evaluate the internal pharmacovigilance processes applied by a pharmaceutical company in response to a potential post-marketing safety signal of stroke associated with a newly authorized biological medicinal product for colorectal cancer. Methods: A structured signal management approach was applied in line with international regulatory guidance. The evaluation included detailed clinical assessment of reported post-marketing cases, review of safety data from completed and ongoing clinical trials, epidemiological comparison with background stroke incidence, assessment of potential risk factors, and review of the pharmacological and biological plausibility. Additional data sources, including scientific literature, safety databases, and periodic safety reports, were systematically reviewed. Multidisciplinary collaboration among pharmacovigilance, medical, and regulatory teams supported the assessment and regulatory interactions. Results: The cumulative evidence did not allow confirmation of a definitive causal relationship between the medicinal product and stroke but identified the event as a potential safety signal requiring close monitoring. The assessment supported the preparation of an evidence-based company position and informed discussions with regulatory authorities, including the European Medicines Agency. Conclusions: This case illustrates the practical implementation of structured signal management in the post-marketing setting. Timely evaluation, interdisciplinary coordination, and regulatory engagement are essential to ensure patient safety, maintain regulatory compliance, and support informed benefit–risk decision-making for innovative biological medicinal products.
- 15 May 2026
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of a Post-Marketing Safety Signal Associated with a Novel Innovative Medicinal Product and Coordination with Regulatory Authorities
Background/Objectives: Following the market authorization of innovative medicinal products, continuous monitoring of safety signals is essential to ensure a favorable benefit–risk balance. This is particularly relevant for biological therapies used in oncology, where complex mechanisms of action and patient-related risk factors may contribute to rare but serious adverse events. The objective of this paper is to describe and critically evaluate the internal pharmacovigilance processes applied by a pharmaceutical company in response to a potential post-marketing safety signal of stroke associated with a newly authorized biological medicinal product for colorectal cancer. Methods: A structured signal management approach was applied in line with international regulatory guidance. The evaluation included detailed clinical assessment of reported post-marketing cases, review of safety data from completed and ongoing clinical trials, epidemiological comparison with background stroke incidence, assessment of potential risk factors, and review of the pharmacological and biological plausibility. Additional data sources, including scientific literature, safety databases, and periodic safety reports, were systematically reviewed. Multidisciplinary collaboration among pharmacovigilance, medical, and regulatory teams supported the assessment and regulatory interactions. Results: The cumulative evidence did not allow confirmation of a definitive causal relationship between the medicinal product and stroke but identified the event as a potential safety signal requiring close monitoring. The assessment supported the preparation of an evidence-based company position and informed discussions with regulatory authorities, including the European Medicines Agency. Conclusions: This case illustrates the practical implementation of structured signal management in the post-marketing setting. Timely evaluation, interdisciplinary coordination, and regulatory engagement are essential to ensure patient safety, maintain regulatory compliance, and support informed benefit–risk decision-making for innovative biological medicinal products.
- Open Access
- 1 May 2026
- Published by KEAI Publishing in Current Pharmaceutical Analysis
- Vol. 22 (4) , 339-347
Integrated RP-HPLC-FTIR investigation of impurity interconversion and excipient-mediated degradation of venlafaxine tablets
- 1 May 2026
- Published by KEAI Publishing in Current Pharmaceutical Analysis
- Vol. 22 (4) , 339-347
Open AccessIntegrated RP-HPLC-FTIR investigation of impurity interconversion and excipient-mediated degradation of venlafaxine tablets
- Open Access
- 1 March 2026
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 76 (1) , 1-25
Predictive analytical workflow for rapid structure elucidation and in silico toxicological qualification of an unidentified impurity in cefixime granules for oral suspension
During in-use stability testing of cefixime granules for oral suspension, an impurity with a relative retention time of 0.19 was consistently detected and increased during storage. To ensure regulatory compliance and patient safety, the impurity was structurally identified and toxicologically qualified. A laboratory-scale formulation and commercial products were studied under refrigerated and ambient conditions. The impurity was isolated by automated fraction collection and characterised by liquid chromatography-mass spectrometry and tandem mass spectrometry. Kinetic evaluation showed pseudo-first-order formation, with faster accumulation at ambient temperature. The impurity was identified as a γ -lactone degradation product of cefixime, present as multiple stereoisomers stabilised under acidic conditions. In silico toxicological assessment using complementary platforms indicated no additional structural alerts, no mutagenic potential, and negligible acute toxicity. The impurity forms only after prolonged storage of reconstituted suspensions and is classified as an ICH M7 Class 5 impurity, requiring no further genotoxicity testing. The applied analytical-computational workflow provides an efficient approach for impurity qualification in β -lactam antibiotics.
- 1 March 2026
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 76 (1) , 1-25
Open AccessPredictive analytical workflow for rapid structure elucidation and in silico toxicological qualification of an unidentified impurity in cefixime granules for oral suspension
During in-use stability testing of cefixime granules for oral suspension, an impurity with a relative retention time of 0.19 was consistently detected and increased during storage. To ensure regulatory compliance and patient safety, the impurity was structurally identified and toxicologically qualified. A laboratory-scale formulation and commercial products were studied under refrigerated and ambient conditions. The impurity was isolated by automated fraction collection and characterised by liquid chromatography-mass spectrometry and tandem mass spectrometry. Kinetic evaluation showed pseudo-first-order formation, with faster accumulation at ambient temperature. The impurity was identified as a γ -lactone degradation product of cefixime, present as multiple stereoisomers stabilised under acidic conditions. In silico toxicological assessment using complementary platforms indicated no additional structural alerts, no mutagenic potential, and negligible acute toxicity. The impurity forms only after prolonged storage of reconstituted suspensions and is classified as an ICH M7 Class 5 impurity, requiring no further genotoxicity testing. The applied analytical-computational workflow provides an efficient approach for impurity qualification in β -lactam antibiotics.